Mucopolysaccharidoses – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of mucopolysaccharidosis (MPS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of MPS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s MPS forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MPS over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following MPS patient populations:

  • Diagnosed prevalence of MPS.
  • Diagnosed prevalence of MPS I.
  • Diagnosed prevalence of MPS II.
  • Diagnosed prevalence of MPS III.
  • Diagnosed prevalence of MPS IV.
  • Diagnosed prevalence of VI.
  • Diagnosed prevalence of MPS VII.

Table of contents

  • Mucopolysaccharidoses - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Diagnosed Prevalence of Mucopolysaccharidosis per 100,000 People of All Ages in 2019 and 2039ttttttttt
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis I
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis I by Subtype
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis II
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis III
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis III by Subtype
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis IV
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis IV by Subtype
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis VI
      • Diagnosed Prevalent Cases of Mucopolysaccharidosis VII
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Mucopolysaccharidosis
        • Studies Excluded from the Analysis of Mucopolysaccharidosis
      • Risk/Protective Factors
        • Risk/Protective Factors for Mucopolysaccharidosis
      • Bibliography